A prediction model to select PCOS patients suitable for IVM treatment based on anti-Müllerian hormone and antral follicle count

Human Reproduction

Volumn 28, Issue 5, 2013, Pages 1261-1266

  Guzman, L ^a   Ortega Hrepich, C ^a   Polyzos, N P ^a   Anckaert, E ^b   Verheyen, G ^a   Coucke, W ^c   Devroey, P ^a   Tournaye, H ^a   Smitz, J ^b   De Vos, M ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; PROGESTERONE; TESTOSTERONE;

ADULT; AMENORRHEA; ARTICLE; BODY MASS; COHORT ANALYSIS; DISEASE DURATION; EMBRYO TRANSFER; ENDOMETRIAL THICKNESS; FEMALE; HUMAN; HUMAN CELL; IN VITRO OOCYTE MATURATION; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OLIGOMENORRHEA; OOCYTE; OOCYTE RETRIEVAL; OVARY FOLLICLE; OVARY FOLLICLE CELL; OVARY POLYCYSTIC DISEASE; PATIENT SELECTION; PREDICTIVE VALUE; PREGNANCY RATE; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL;

EID: 84876552652     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det034     Document Type: Article

References (23)

1. Albertini DF, Barrett SL. Oocyte-somatic cell communication. Reprod Suppl 2003;61: 49-54.
2. Albuz FK, Sasseville M, Lane M, Armstrong DT, Thompson JG, Gilchrist RB. Simulated physiological oocyte maturation (SPOM): a novel in vitro maturation system that substantially improves embryo yield and pregnancy outcomes. Hum Reprod 2010;25: 2999-3011.
3. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 2009;91: 705-714.
4. Child TJ, Abdul-Jalil AK, Gulekli B, Tan SL. In vitro maturation and fertilization of oocytes from unstimulated normal ovaries, polycystic ovaries, and women with polycystic ovary syndrome. Fertil Steril 2001; 76: 936-942. (Pubitemid 33031319)
5. Child TJ, Phillips SJ, Abdul-Jalil AK, Gulekli B, Tan SL. A comparison of in vitro maturation and in vitro fertilization for women with polycystic ovaries. Obstet Gynecol 2002a;100: 665-670. (Pubitemid 35300020)
6. Child TJ, Sylvestre C, Pirwany I, Tan SL. Basal serum levels of FSH and estradiol in ovulatory and anovulatory women undergoing treatment by in-vitro maturation of immature oocytes. Hum Reprod 2002b; 17: 1997-2002.
7. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002;77: 141-146. (Pubitemid 34093906)
8. De Vos M, Ortega-Hrepich C, Albuz FK, Guzman L, Polyzos NP, Smitz J, Devroey P. Clinical outcome of non-hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome. Fertil Steril 2011;96: 860-864.
9. Devroey P, Polyzos NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011;26: 2593-2597.
10. Fadini R, Dal Canto MB, Renzini MM, Brambillasca F, Comi R, Fumagalli D, Lain M, De Ponti E. Predictive factors in in-vitro maturation in unstimulated women with normal ovaries. Reprod Biomed Online 2009; 18: 251-261.
11. Fadini R, Comi R, Mignini Renzini M, Coticchio G, Crippa M, De Ponti E, Dal Canto M. Anti-Mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment. J Assist Reprod Genet 2011;28: 501-508.
12. Guzman L, Ortega-Hrepich C, Albuz FK, Verheyen G, Devroey P, Smitz J, De Vos M. Developmental capacity of in vitro-matured human oocytes retrieved from polycystic ovary syndrome ovaries containing no follicles larger than 6 mm. Fertil Steril 2012;98: 503-507 e502.
13. Harper J, Magli MC, Lundin K, Barratt CL, Brison D. When and how should new technology be introduced into the IVF laboratory? Hum Reprod 2012;27: 303-313.
14. Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010; 94: 389-400.
15. Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89: 318-323. (Pubitemid 38183899)
16. Mikkelsen AL, Smith S, Lindenberg S. Impact of oestradiol and inhibin A concentrations on pregnancy rate in in-vitro oocyte maturation. Hum Reprod 2000;15: 1685-1690. (Pubitemid 30636053)
17. Mikkelsen AL, Andersson AM, Skakkebaek NE, Lindenberg S. Basal concentrations of oestradiol may predict the outcome of in-vitro maturation in regularly menstruating women. Hum Reprod 2001; 16: 862-867. (Pubitemid 32451818)
18. Nardo LG, Yates AP, Roberts SA, Pemberton P, Laing I. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome. Hum Reprod 2009;24: 2917-2923.
19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19: 41-47.
20. Shalom-Paz E, Marzal A, Wiser A, Almog B, Reinblatt S, Tulandi T, Holzer H. Effects of different body mass indices on in vitro maturation in women with polycystic ovaries. Fertil Steril 2011; 96: 336-339.
21. Smitz JE, Thompson JG, Gilchrist RB. The promise of in vitro maturation in assisted reproduction and fertility preservation. Semin Reprod Med 2011; 29: 24-37.
22. Son WY, Tan SL. Laboratory and embryological aspects of hCG-primed in vitro maturation cycles for patients with polycystic ovaries. Hum Reprod Update 2010;16: 675-689.
23. Tan SL, Child TJ. In-vitro maturation of oocytes from unstimulated polycystic ovaries. Reprod Biomed Online 2002;4: 18-23.